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Manuscript received November 17, 2017 and accepted March 14, 2018AbstractThe vascular endothelial growth factor (VEGF) signaling pathway (VSP) fulfills a cardinal role in endothelial cells and its inhibi-
tion has profound cardiovascular impact. This is true not only for the normal vasculature but also for the tumor vasculature when
VSP inhibitors are used as anti-angiogenic therapies. Generalized endothelial dysfunction predisposes to vasoconstriction, athero-
sclerosis, platelet activation, and thrombosis (arterial more than venous). All of these have been reported with VSP inhibitors and
collectively give rise tovascular toxicities, themost concerning ofwhich are arterial thromboembolic events (ATE).VSP inhibitors
include antibodies, acting extracelluarly on VEGF, such as bevacizumab and tyrosine kinases inhibitors, acting intracellularly on
the kinase domain of VEGF receptors, such as sunintib and sorafenib. The addition of bevacizumab and VSP tyrosine kinase in-
hibitor therapy to the cancer treatment regimen is associated with a 1.5–2.5-fold and 2.3–4.6-fold increase risk of ATEs, respec-
tively. Risk factors for ATEs while on VSP inhibitor therapy include age older than 65 years, previous thromboembolic events,
history of atherosclerotic disease, and duration of VSP inhibitor therapy. In clinical practice, hypertension remains the most
commonly noted vascular manifestation of VSP inhibition. Optimal blood pressure goals and preferred therapeutic strategies to-
ward reaching these goals are not defined at present. This review summarizes current data on this topic and proposes a more inten-
sive management approach to patients undergoing VSP inhibitor therapy including Systolic Blood PRessure Intervention Trial
(SPRINT) blood pressure goals, pleiotropic vasoprotective agents such as angiotensin converting enzyme inhibitors, amlodipine,
and carvedilol, high-dose statin therapy, and aspirin. JAmSocHypertens 2018;12(6):409–425. 2018 TheAuthors. Published by
Elsevier Inc. on behalf of American Society of Hypertension. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
Keywords: Angiogenesis inhibitors; cardiovascular events; chemotherapy; hypertension.The concept that growth of tumors is related to their
vascular supply was first described over 100 years ago.1,2
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016/j.jash.2018.03.008blood vessels (angiogenesis) and that blocking angiogen-
esis could be a strategy to inhibit tumor progression.
Vascular endothelial growth factor (VEGF) is one of the
most important growth factors to promote angiogenesis
and changes in the tumor microenvironment. In agreement,
drugs that block the VEGF signaling pathway (VSP) have
expanded the therapeutic options for several solid tumor
cancers, such as metastatic colorectal cancer, non-small
cell lung cancer, and gliobastoma.3–5 One of the most
classic examples, however, is metastatic renal cell carci-
noma (mRCC), for which VSP inhibitors have doubled
response and overall survival rates.6 By 2016, the USAmerican Society of Hypertension. This is an open access article
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genic drugs as either first- or second-line therapy for
mRCC, all of these targeting the VEGF signaling. VSP in-
hibitors, including sorafenib (Nexavar, Bayer), sunitinib
(Sutent, Pfizer), bevacizumab (Avastin, Genentech), pazo-
panib (Votrient, Novartis), axitinib (Inlyta, Pfizer), cabo-
zantinib (Cometriq, Exelixis), and lenvatinib (Lenvima,
Eisai) have been especially effective in renal cell carcinoma
(RCC) based on the link with the von Hippel-Lindau gene/
protein. This tumor suppressor gene/protein targets hypox-
ia-inducible factor (HIF), the transcription factor involved
in VEGF expression, to ubiquitin-mediated proteasomal
degradation and its inactivation (which leads to increased
HIF and thus VEGF levels) has been implicated in the path-
oetiology of (clear) RCC.7
Since angiogenesis does not initiate but is involved in the
maintenance and dissemination of the malignant process,
angiogenesis inhibitors, for the most part, contain, but do
not eliminate, cancers. This unique efficacy goes along
with long, chronic treatment times, and evolving toxicities
can become quite relevant for the individual cancer pa-
tient.8 Growing evidence demonstrates that cancer patients
treated with VSP inhibitors, including direct VEGF inhibi-
tors such as anti-VEGF antibodies or decoy receptors, and
small molecule VEGF tyrosine kinase inhibitors (TKIs), are
at increased risk of developing cardiovascular disease
(CVD). Adverse vascular and cardiac events are rarely a
reason for discontinuation of VSP inhibitor therapy, but
they are important causes for fatal outcomes. In fact,
25%–66% of all fatal events in VSP-treated cancer patients
are vascular in nature, especially hypertension, arterial
thromboembolism, myocardial infarction, and cerebrovas-
cular disease.9 Worth to mention in this context is that sem-
axinib, the first oral VSP-TKI to enter clinical trials, was
withdrawn after a high rate of thromboembolism was noted
in combination therapies (42% arterial thromboembolic
events [ATEs] when combined with gemcitabine andFigure 1. Bar graph illustrating the number needed to treat to
cause one of the indicated CV events (based on data from13).
HTN, hypertension; ATE, arterial thromboembolic events;
HF, heart failure.cisplatin and 25% VTEs when combined with pacli-
taxel).10–12
A recent meta-analysis of 77 studies reported that over
1200 patients need to be treated with VSP inhibitors for
one fatal event to occur, and overall survival is not
reduced.13 Such data might argue against the greater clin-
ical relevance of these cardiovascular (CV) side effects in
a cancer population in need of therapy. At the very least,
these data make the point that any untoward side effects
must be balanced against the perceived benefit. As such,
familiarity with these events is important as is the appro-
priate management. Figure 1 illustrates the risks of CV
events in terms of numbers needed to harm,13 and this re-
view will focus on the vascular toxicities of VSP inhibitor
therapy, related to hypertension, altered vascular reac-
tivity, accelerated atherosclerosis, and acute arterial
events. A summary of incidences of vascular events with
VSP inhibitors and chemotherapeutics in general is pro-
vided in Table 1.
Incidence and Risk Factors for Systemic
Hypertension with VSP Inhibitors
Almost all clinical trials have demonstrated that VSP in-
hibitors cause an increase in blood pressure, with 30%–
80% of patients developing hypertension.14,15 Initial studies
with bevacizumab found a 20%–30% higher than expected
risk of hypertension, but the need for (intensification of)
antihypertensive therapy was only seen in 10%–20% of pa-
tients, and life-threatening hypertensive crisis occurred in
only approximately 1% of patients.16,17 It is important to
recognize that event rates are critically dependent on the
definition, assessment, and adjudication of events. For
instance, the incidence of hypertension with bevacizumab
(all grades) is more than double with home than with office
blood pressure measurements (55% vs. 24%).18 Home
blood pressure monitoring, conducted appropriately after
adequate instructions, is more sensitive to detect milder
and earlier stages of hypertension. The argument that the
use of clinical cancer trial criteria could have confounded
the incidences is addressed by the observation that the hy-
pertension criteria of the European Society of Hypertension
and the National Cancer Institute Common Toxicity
Criteria (NCI-CTC), version 3.0, yielded fairly
comparable detection rates in the office-based setting.18 It
is important though that an appropriately calibrated device
with a correctly sized cuff is used, and ideally a minimum
of two measurements several minutes apart are taken and
averaged.
The first report on automated ambulatory blood pressure
monitoring (ABPM) in patients with mRCC on sunitinib
showed an average increase in systolic and diastolic blood
pressure by 14 mmHg and 11 mmHg, respectively, in the
first week and by 22 mmHg and 17 mmHg, respectively, af-
ter 4 weeks (Figure 2).19 It also demonstrated that
Table 1
Incidence of vascular toxicities with chemotherapeutics (based on Micromedex and Lexicomp)




5-Fluorouracil ND ND ND ND
Capecitabine <1 6 1–10 <1 <1 <1
Gemcitabine <1 <1 <1
Antimicrotubule agents
Paclitaxel 1 <1 <1 1
Alkylating agents
Cisplatin 3 2 <1 <1 <1
Cyclophosphamide <1 <1 <1
Antitumor antibiotics
Bleomycin <1 <1 <1 <1 <1
Vinca alkaloids
Vincristine ND ND ND ND
mTOR inhibitors
Everolimus 4–13 5 <1 1–10
Temsirolimus 7 16 2
Proteasome inhibitors
Bortezomib 6 ND ND ND ND
Carfilzomib 15–42 3–21 <20 2
Monoclonal antibodies
Bevacizumab 19–42 8 6 (ATE) 6 (ATE) 6–14
Ramucirumab 11–36 2 (ATE) 2 (ATE)
Rituximab 6–12 <1 <1
VEGF-receptor fusion
molecules
Aflibercept 41 3 (ATE) 3 (ATE) 5–9
Tyrosine kinase
inhibitors
Sorafenib 9–41 <1 3 <1 <1
Sunitinib 15–34 13 <1 1 3
Pazopanib 40–42 5–10 2 1 5
Axitinib 40 <1 2 1 1–3
Regorafenib 30–59 1 1
Cabozantinib 33–61 2 (ATE) 2 (ATE) 4–7
Vandetanib 33 1%
Lenvatinib 42–73 7–10 3–5
Nilotinib 10 5–9 1 1–3 3–4 ND





Dasatinib 4 ND <1
Miscellaneous
Interferon-alpha 2B 9 28 <5 <5 <5 <5 <5 <5
Thalidomide 23
Lenalidomide 6–8 5–8 5 2 2–10
AMI, acute myocardial infarction; ATE, arterial thromboembolic events; DVT, deep vein thrombosis; HTN, hypertension; mTOR,
mammalian target of rapamycin; ND, frequency not defined; PAD, peripheral arterial disease; PE, pulmonary embolism; VEGF, vascular
endothelial growth factor.
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falls quickly, within 1 week. In initially normotensive pa-
tients, the blood pressure may not return to pre-therapy
levels after the first cycle; rather it is reset to a new baseline
that is several points higher. It is for this reason that higherblood pressure values are reached with the second cycle.
Multiple resets are not necessarily seen though, and the dy-
namics are responsive to antihypertensive therapy. Indeed,
adjustment in antihypertensive therapy can fully blunt hy-
pertensive responses on VSP inhibitor therapy.
Figure 2. Illustration of systolic and diastolic blood pressures of patients undergoing treatment with sunitinib, stratified by baseline his-
tory of hypertension, absent (panel A) or present (panel B).
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blood pressures occur rapidly, often within hours, and
circadian blood pressure dynamics are typically lost or
significantly attenuated. In a mixed cohort of patients
receiving sorafinib, the average increase in blood pressure,
within the first day of treatment, was 7/6 mmHg. A further
increase was noted during days 6–10, followed by a plateau
as steady-state concentrations of the drug equilibrated.20
Overall, 93% of patients had an increase in the mean arte-
rial blood pressure (MAP) from 2 to 27 mmHg in the
plateau stage. Of these, 28% had an increase less than twice
the limit of detection for change, and 16% had an increase
two times the average change of 16.7 mmHg of MAP.20
Likewise in ovarian cancer patients receiving cedarinib,
almost all (95%) of patients had an increase in blood pres-
sure within 3 days but of variable degree (average increase
19 mmHg systolic, 17 mmHg diastolic, MAP increase from
2 to 55 mmHg, most <35 mmHg, in two-thirds of relevant
change).21
Even within the same study population, exposed to the
same treatment regimen, considerable variability in the
blood pressure response can be seen. Age 60years, body
mass index 25 kg/m2, and pre-hypertension were identi-
fied as predictors of a hypertensive response, each adding
an absolute 10% increase in risk to a baseline risk without
any risk factors of 30%.22 Other studies, however, were un-
able to verify these or any other predictors.20 Accordingly,
all patients should undergo blood pressure monitoring,
especially as this is an easy and inexpensive test.Clinical Implications of Systemic Hypertension
with VSP Inhibitors
Awareness and monitoring are geared to recognize and
appropriately manage blood pressure elevations in cancer
patients on VEGF inhibitor therapy. In the general popula-
tion, blood pressure management serves the purpose of
primary (and secondary) prevention of CVD and events
long-term. This used to rarely apply to cancer patients
with limited exposure and life expectancy. This argument,
however, may not hold any more with improvement in sur-
vival outcomes and chronicity of cancer treatment.
While often not considered detrimental, even short-term
increases in blood pressure can have serious implications in
cancer patients on VEGF inhibitor therapy. The conse-
quences include acute ischemic and hemorrhagic events,
flash pulmonary edema, and reversible posterior leukoence-
phalopathy. Chronic blood pressure elevations stimulate a
hypertrophic response in the myocardium, which is
matched by a compensatory angiogenic response. In cancer
patients on VSP inhibitor therapy, this compensatory
response is inhibited, predisposing to myocardial maladap-
tion to pressure load and ‘‘cardiotoxicity’’. Hypertension is
a potent risk factor for atherosclerosis, its complications, as
well as atrial fibrillation, all of which can complicate the
care of cancer patients significantly. Uncontrolled hyperten-
sion is conceivably of much greater risk in patients with
additional CV risk factors and especially CVD. Interest-
ingly, hypertension with VEGF inhibitor therapy is not a
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apy.21 This is in agreement with experimental studies point-
ing out that proteinuria and renal injury including
glomerular ischemia develop as a function of VEGF inhib-
itor dose. Hypertension occurs before proteinuria manifests
and is evident at lower doses of VSP inhibitors than those
that cause proteinuria.21 Hence, hypertension, proteinuria,
and renal dysfunction are not causally linked in VSP
inhibitor-treated patients.23 In RCC patients with solitary
kidneys after nephrectomy, these aspects are especially
relevant. Renal dysfunction secondary to VSP inhibitor
use is beyond the scope of this review but is covered
elsewhere.17,24
It is also beyond the scope of this review to fully discuss
the merit of systemic hypertension as a ‘‘biomarker’’ for
the anticancer activity and efficacy of VEGF therapy. For
instance, in patients on treatment with sunitinib for
mRCC, overall survival was almost 2 years longer in those
with systolic blood pressure increases to 140 mmHg.25
Several other but importantly not all studies have made
similar observations. As such, hypertension may serve asFigure 3. Illustration of possible pathophysiological processes, where
receptor) inhibition contributes to the development of hypertension
including monoclonal VEGF antibodies, anti–VEGF-R2 antibodies, so
tyrosine kinase inhibitors (TKIs), are used clinically as antiangiogenes
consequent reduction in production of vasodilators (NO and PGI2), inc
rarefaction, resulting in increased vascular tone and arterial remodelin
contribute to volume overload. Ab, antibody; CVD, cardiovascular dis
ide; p, phosphorylation site of tyrosine kinase; PGI2, prostaglandin I2;
NN, Herrmann J, van den Meiracker AH, Danser AHJ. Recent Advanc
hibition. Hypertension. 2017; 70:220-226).a reflection of the on-target effects of VEGF inhibitors in
cancer patients and the vascular changes occurring on tu-
mor level.
Another aspect of interest in this regard is the produc-
tion of VEGF-A splice variants in cancers such as
VEGF-A165b.26,27 This splice variant is capable of bind-
ing to VEGF receptor-2 (R2) but with inhibitory effects,
thus decreasing the angiogenic tumor response.28 More-
over, VEGF-A165b binds bevacizumab with the same af-
finity as VEGF-A165, therefore reducing the therapeutic
efficacy of bevaciumab as well.29 In the presence of circu-
lating VEGF-Axxxb splice variants, the neutralizing ef-
fects on bevacizumab would be on a much larger scale.
These patients would be expected to have a much less
than expected blood pressure increase on therapy. It is
not expected that VSP-TKIs would be neutralized by
VEGF-Axxxb splice variants in a manner similar to beva-
cizumab. However, in the presence of VEGF-A165b and
its inhibitory effects on VEGF-R2 signaling with reduced
activity (phosphorylation) of the receptor tyrosine kinase
and activation of downstream signaling pathways,by VEGF (vascular endothelial growth factor)–VEGFR (VEGF
and CVD. Four major classes of VEGF–VEGFR inhibitors,
luble decoy receptors (VEGF-traps), and small molecule VEGFR
is drugs in cancer. The effects are reduced VEGFR signaling and
reased production of vasoconstrictors (ET-1), oxidative stress and
g. Reduced pressure natriuresis and impaired lymphatic function
ease; ECF, extracellular fluid; ET-1, endothelin-1; NO, nitric ox-
ROS, reactive oxygen species. (Modified from Touyz RM, Lang
es in Hypertension and Cardiovascular toxicities with VEGF In-
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setting then again, an attenuation of the treatment effect
and possibly vascular effects could be anticipated.
Accordingly, one could make an argument that testing
for splice variants and quantification of the ratio of
VEGF-Axxx to VEGF-Axxxb splice variants may serve
as a predictor of vascular side effects with therapy. It
would need to be combined with a preparation of what
to do therapeutically for these cancer patients. In sum-
mary, monitoring blood pressure dynamics in cancer pa-
tients on VEGF inhibitor therapy can provide important
clues to the molecular tumor environment and response
to therapy as it relates to this key angiogenesis factor.
Mechanisms of Systemic Hypertension with VSP
Iinhibitors
Various mechanisms for the development of hypertension
with VEGF inhibitor therapy have been suggested
(Figure 3). In a classical contribution, Horowitz et al.
demonstrated that VEGF administration to live animals re-
sults in a predictable hypotensive response, which can be
antagonized by inhibition of nitric oxide (NO) synthase
(NOS).30 Conversely, administration of a VEGF-R2 antibody
causes a rapid and sustained increase in blood pressure, and
differences between treated and untreated animals are
abolished by NOS inhibition.31 No activation of the renin-
angiotensin system was noted in this setting; rather, endothe-
lial and neuronal NOS expression in the kidney was
suppressed. The important role of NO in the regulation of
(medullary) renal blood flow and (tubular) sodium excretion
has been recognized for a long time and it has been postu-
lated that inhibition or deficiency of NOS would result in
sustained hypertension.30 Thus, while renal dysfyunction is
not the initial cause of hypertension in patients on VEGF in-
hibitor therapy, inhibition of renal NO signaling is associated
with a rightward shift of the renal pressure-natriuresis curve,
impaired sodium excretion, and consequently fluid retention
and salt-dependent hypertension.14
While it is clear that VEGF inhibition interferes with NO
signaling pathway activity, even in humans, it has remained a
matter of debate how the interplay between VSP inhibitors
and NO affects the vasculature and its contributions to blood
pressure elevations.32 In vascular terms, the cardinal sign of
reduced NO production and/or availability is endothelial
dysfunction. This condition is classically recognized by
impairment of endothelium-dependent vasodilation in
response to acetylcholine. In healthy volunteers, that is, in
the absence of any comorbid condition and treatment that
could alter the response, bevacizumab at clinically relevant
treatment concentrations very specifically and acutely
(within 15 minutes) reduced endothelium-dependent vasodi-
lation.33 No increase in vascular tone or blood pressure was
noted in this particular study, and subsequent work showed
that impairment of endothelium-dependent vasodilationdoes not precede the development of hypertension in patients
on sunitinib arguing against a direct causal link.34 In agree-
ment, while tivozanib and telatinib reduced flow-mediated
dilatation in patients over a treatment period of 8 and 6
weeks, respectively, vandetanib over 6 weeks had no such ef-
fect even though it did decrease plasma nitrate/nitrite levels
and resting brachial artery diameter and all drugs signifi-
cantly increased systemic blood pressures.35–37 Clearly, the
impact of VSP-TKIs is much more complex and likely
related to the additional ‘‘off-target’’ effects. Along these
lines, bevacizumab is a much ‘‘cleaner’’ drug, and reports
confirm similar impairment of flow-mediated dilation after
6 weeks of bevacizumab therapy as well as increase in pulse
wave velocity indicative of increased arterial stiffness.38 As
such, there is a definite effect of VEGF inhibition on the
vasculature, and as outlined in other experimental studies,
the net effect that can be linked to blood pressure elevation
is an increase in systemic vascular resistance.39 Stimulation
of the endogenous endothelin (ET) system seems to relate to
these changes even if the endothelium is not the source of the
elevated ET-1 levels, which have been confirmed in patients
as well.40 One may argue that capillary rarefaction, observed
in animal models and patients on VSP inhibitor therapy, is a
responsible factor for the increased systemic resistance.
However, it has been estimated that a 40% reduction of
fourth order vessels is required for a 5% increase in vascular
resistance, and it seems very unlikely for this to occur over
the course of a few hours.39 As seen in patients with idio-
pathic (essential) hypertension, capillary rarefaction may
be the consequence rather than the cause of hypertension
in patients undergoing VEGF inhibitor therapy.33 This is
not to say though that eventually it contributes to the sus-
tained blood pressure elevations. Likewise, it cannot be ruled
out that a declining NO activity is unmasking the activity of
the endogenous ET system, and that oxidative stress has a
permissive or contributory role.33,41,42 As a final point,
much of what has been discussed mirrors discussions and
findings of women with preeclampsia. A common link
would be the high levels of soluble VEGF-R1 in these
women, which sequesters VEGF in a manner similar to bev-
acizumab and afilbercept.15
Monitoring and Management of Systemic VSP
Inhibitor-Induced Hypertension
There is currently no formal guideline on the type of
blood pressure monitoring in patients on VSP inhibitor
therapy (office single reading vs. office average of multiple
readings vs. home monitoring vs. ABPM). The Cardiovas-
cular Toxicities Panel, Convened by the Angiogenesis Task
Force of the National Cancer Institute Investigational Drug
Steering Committee, recommended that blood pressures
should be monitored weekly during the first cycle of
VEGF inhibitor therapy, and once stable blood pressures
are achieved, depending on the level of risk for
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conveniently aligned with home blood pressure monitoring
or routine clinical evaluations, at least every 2–3 weeks for
the remainder of treatment.43 Based on the sometimes pro-
found blood pressure dynamics, however, more frequent
blood pressure measurements (daily) might be required,
and a baseline measurement is mandatory.
The same panel recommended less than 140/90 mmHg
as the goal for blood pressure control in patients on
VEGF inhibitor therapy in general and less than 130/
80 mmHg for patients with diabetes and/or chronic kidney
disease.43 This was in keeping with the Joint National
Committee VII guidelines at the time, which since then
have changed, (ie Joint National Committee VIII metrics:
150/90 mm Hg or higher in patients 60 years and older,
or 140/90 mmHg or higher in patients younger than 60
years or with diabetes). Indeed, a more lenient approach
with a goal of 150/100 in a phase II trial protocol was
shown to be safe and effective.44 On the other hand, the sys-
tolic blood pressure intervention trial (SPRINT) trial data
would suggest a benefit from a more aggressive approach
with a systolic blood pressure goal of <120 mmHg (rather
than the outline standard goal of <140 mmHg systolic).45
Even though on average, the intensive therapy cohort
remain just around 120 mmHg, a 25% reduction in the pri-
mary endpoint of myocardial infarction (MI), acute coro-
nary syndrome, stroke, heart failure, and death from CV
causes emerged after 1 year. This was driven by a 38%
reduction of heart failure events and a 43% reduction of
CV death. Overall mortality was also reduced significantly
by 27%. Patients without chronic kidney disease faced a 3.5
times higher risk of glomerular filtration rate decline by
30% – <60 mL/min/m2. Importantly, patients were
required to be at increase CV risk by one or more of the
following: clinical or subclinical CVD other than stroke;
chronic kidney disease with an estimated glomerular filtra-
tion rate of 20 to less than 60 mL per minute per 1.73 m2 of
body surface area, a 10-year risk of CVD of 15% or greater
on the basis of the Framingham risk score; or an age of 75
years or older; patients with diabetes mellitus or prior
stroke were excluded. Based on the results of this and
several other trials, as well as meta-analyses on this subject,
the American Heart Association along with 10 other soci-
eties released the 2017 guidelines for the prevention, detec-
tion, evaluation, and management of high blood pressure in
adults.46 These guidelines recommend the use of BP-
lowering medications for secondary prevention of CV
events in patients with clinical CVD and an average systolic
blood pressure of 130 mmHg or higher or an average dia-
stolic blood pressure of 80 mmHg or higher, and for pri-
mary prevention in adults with an estimated 10-year
atherosclerotic cardiovascular disease (ASCVD) risk of
10% or higher and an average systolic blood pressure
130 mmHg or higher or an average diastolic blood pressure
80 mmHg or higher.46We propose that for cancer patients on VEGF inhibitor
therapy, the same strict blood pressure goals should be pur-
sued. This is not limited to secondary prevention efforts,
and we would argue that these patients meet primary pre-
vention criteria and face a 10-year risk of CVD of 15%
or more by SPRINT criteria. In a study of prostate cancer
patients undergoing therapy with bevacizumab, a history
of myocardial infarction, angina, peripheral arterial disease,
arterial thrombosis, transient ischemic attack, or stroke
increased the risk of an ATE by a factor of 2.29 (0.83–
5.68). In comparison, bevacizumab treatment was a stron-
ger and even more robust predictor (3 [1.25–7.19],
P ¼ .01).47 Furthermore, the event rate of ATEs was
3.8% over 21 months, which calculates into an event rate
of 21.7% over 10 years. In metastatic cancer patients under-
going bevacizumab therapy, 5% developed an ATE over 15
months, which calculates into a 10-year event rate of
40%.48 Finally, the ATE event rate attributed to bevacizu-
mab in the Japanese Adverse Drug Event database was
3.8% over 12 months, which translates into 38% in 10
years.49 For VSP-TKIs, a meta-analysis on sunitinib and
sorafenib concluded on an ATE incidence event rate of
1.4% over 6.8 months, which equates a 10-year risk of
24.7%.50 Accordingly, on bevacizumab or VSP-TKI, can-
cer patients face a rate of ATEs that is well within the
high risk range. What is unknown at this point is if strict
blood pressure control in these patients will lead to fewer
events and improved overall outcomes. The potential for
adverse events needs to be acknowledged, and these pa-
tients will need close follow-up on blood pressure, renal
function, and any evolving signs and symptoms of CVD.
Importantly, the SPRINT trial does indicate that elderly
and frail patients do not fare worse but better with stricter
blood pressure control (Figure 4).51
Every patient, who is to start on VSP inhibitor therapy,
should undergo a thorough evaluation of baseline condition
and comorbidities (Figure 5). Ideally, blood pressure goals
should be accomplished before the initiation of VEGF in-
hibitor therapy. In those on antihypertensive therapy, medi-
cation and diet adherence should be verified otherwise
these are to be intensified. The risks of delaying anticancer
therapy for optimization of the CV status always need to be
balanced with the hazards of incomplete control or subop-
timal management of CVD and risks. For blood pressure
control, shorter acting agents with close follow-up (as
frequently as every 2–4 days) might achieve goals quickly,
and therapy can thereafter be transitioned to equivalent
doses of longer acting agents.
The choice of the specific antihypertensive agent relates
to the underlying mechanisms of systemic hypertension.
Diuretics address the aspect of increased salt sensitivity,
whereas NO donors address NO deficiency. Nitrates have
been used successfully in these patients for resistant hyper-
tension.52 Other vasodilators such as the calcium channel
blocker nifedipine effectively reversed increases in blood
Figure 4. Kaplan–Meier curves for the
primary CVD outcome in systolic blood
pressure intervention trial (SPRINT) in
participants aged 75 years or older by
baseline frailty status. (Reproduced
from51).
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nifedipine did not negatively affect antitumor activity,
which is of relevance as it may increase VEGF levels.33
The latter relates to the induction of CYP3A4, an effect
even more so seen with the calcium channel blockers dilti-
azem and verapamil, which should be avoided in these pa-
tients. Amlodipine has thus been advocated as an
alternative, which similarly prevented the early increase
in blood pressure with VEGF inhibitor therapy.54 Consis-
tent with the view of a mechanistic role of the ET-1 system
in the hypertensive response to VEGF inhibitor therapy,
dual ETa/ETb receptor blockade might be a valid yet not
commonly taken approach. There is no strongly supported
role for beta blocker as a class of drugs in these patients un-
less concomitant cardiac ischemia and evidence for adren-
ergic stimulation. There might, however, be a role for
nebivolol as it increases endothelial NO production and
may counteract the VEGF inhibitor effect. On the other
hand, the same effect might be observed in the tumor
vasculature. Carvedilol, based on its additional vasodilatory
effect, beneficial action on endothelial cells, and reported
antiangiogenic effects, seems to be the beta blocker of
choice in this patient population.55–57
The role of angiotensin converting enzyme (ACE) inhib-
itors is somewhat a matter of debate. In agreement with a
lesser role of the renin-angiotensin system in the mecha-
nism of VSP inhibitor-induced hypertension, captopril
was effective in lowering lower (10 mmHg) but not higher
(35–50 mmHg) degrees of blood pressure elevations in an-
imal models.53,54 Comparable to dual ETa/ETb receptor
blockade, captopril did prevent renal structural changes
and is a preferred option in patients with proteinuria.
Furthermore, four studies in 2014/2015 (three retrospective
single center studies and one meta-analysis of 12 phase IIand III clinical trials) indicated superior survival outcomes
of patients with metastatic renal cell carcinoma, who were
on angiotensin system inhibitors.58–61 Furthermore, in cell
culture experiments, captopril and lisinopril had an additive
benefit to sunitinib in decreasing the viability of renal car-
cinoma cell lines. These results are in agreement with better
outcomes of mice with renal cell carcinoma subjected to
renin angiotensin system (RAS) inhibition.58–61 However,
not all studies are in agreement with a superior action of
RAS inhibitors.62
In keeping with the outlined data and the overall goal to
improve endothelial function and NO availability and to
decrease pathological angiogenesis, one may argue that
ACE inhibitors  amlodipine is the preferred first line ther-
apy for patients with new onset or worsening hypertension
on VSP inhibitor therapy in the absence of any other co-
morbidity that would direct therapy. Carvedilol may be
considered as a third step based on the additional beneficial
vascular actions. For blood pressure control in patients with
refractory hypertension, diuretics þ/- nitrates may enhance
the vasodilatory approach. An outline of a potential
approach to therapy is provided in Figure 6.
Clinical Burden of Altered Vasoreactivity,
Atherosclerosis, and Arterial Events with VSP
Inhibitors
While hypertension is the most notable vascular effect,
patients on VSP inhibitor therapy also encounter a higher
risk of ischemic and thrombotic events. Indeed, chest
pain episodes have been reported in 1%–15% of patients,
ranging from stable angina to acute coronary syndrome.16
Meta-analyses confirm a 1.5 and 2–3 times higher risk of
ATEs with bevacizumab and VEGF receptor TKIs,
Figure 5. Evaluation proposal for cancer
patients undergoing chemotherapy with
hypertension risk such as those targeting
the vascular endothelial growth factor
(VEGF) pathway. Baseline evaluation
should take into account risk factors for
cardiovascular (CV) events, including un-
controlled blood pressure (BP), left ven-
tricular hypertrophy (LVH),
cardiovascular disease (CVD), chronic kid-
ney disease (CKD), diabetes. Ideally pa-
tients should be optimized before starting
chemotherapy and should be followed
more closely early after starting therapy.
In case of severe BP elevation or complica-
tions related or aggravated by it, cessation
of therapy is to be considered. As outlined
in the text, we propose a blood pressure
goal for patients on VEGF inhibitor ther-
apy of <130 mmHg systolic (2017 hyper-
tension guideline) and <120 mmHg
systolic ideally (SPRINT trial target).
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phase II and one phase III trial in patients with colorectal,
breast, and non-small cell lung cancer, the overall incidence
of ATEs was 3.8% versus 1.7% in bevacizumab-treated
versus non-treated patients (incidence of fatal ATEs within
30 days 0.6% vs. 0.3%), calculating into a relative ATE risk
of 2 (95% confidence interval [CI] 1.1–3.8).48 The ATEs
accounted for included angina, arterial thrombosis, myocar-
dial infarction, myocardial ischemia, cerebrovascular
accident, cerebral infarct, and cerebral ischemia. In time-
dependent analyses, the events seem to continue to accumu-
late over time but with a 5% event rate in the first year and a
2.5% event rate in the second year. In agreement with an
earlier rather than later onset, the median time to event
was only 2–3 months. Myocardial (angina and myocardial
infarction) and cerebrovascular (transient ischemic attack
and stroke) events accounted for 40% of the total number
of events each. Bevacizumab was confirmed as an indepen-
dent risk factor (hazard ratio [HR] 1.95, 95% CI 1.04–3.67)
as was age  65 years (HR 2.2, 95% CI 1.2–4). A history of
ATE (including angina pectoris, arterial thrombosis, cere-
bral infarct, cerebral ischemia, cerebrovascular accident,
myocardial infarction, and myocardial ischemia) was the
strongest independent risk factor for an ATE on VSP inhib-
itor treatment (HR 3.65, 95% CI 1.9–6.9). These risks may
be additive, as patients with the combination of all three
had an 8.3-fold increased risk of ischemic events. In the
univariate analysis, for those with a history of ATE, a his-
tory of MI carried the strongest risk (HR 4.9, 95% CI
2.6–9.4). Hypertension at baseline was a weaker risk factor
(HR 1.89, 95% CI 1.1–3.3), and neither MI nor hyperten-
sion was an independent predictor of ATEs. Of furtherinterest, patients with a history of ATE had the poorest
overall and progression-free survival.48
Two subsequent meta-analyses on 20 RCTs in patients
with colorectal, breast, non-small cell lung, renal cell,
and pancreatic cancer (all but one being the same) reached
the same conclusions.63,64 All grade ATEs occurred in 3.3%
of the patients on bevacizumab, grade 3 or higher in 2%,
and fatal in 0.4% (five strokes, two MIs). The calculated
relative risks (RRs) for all grade ATEs were 1.44 in one
and 1.46 in the other study (95% CI 1.1–1.9). The highest
incidences were noted in colorectal cancer patients (3%–
6%), which constituted the largest group of patients.
Among the different types of ATEs, the highest risk was
noted for high-grade cardiac ischemia (summary incidence
1.5%, RR 2.1 [95% CI, 1.12–4.08]). There was no differ-
ence in risk by treatment duration or dose intensity.
A subsequent meta-analysis of seven phase II and III tri-
als RCTs, looking specifically at myocardial ischemic end-
points (myocardial infarction, unstable angina, coronary
revascularization, coronary artery disease (CAD), arrhyth-
mias, sudden cardiac death, or CV-related death) and
including two more studies than in the analysis by Ranpura
et al., confirmed an overall RR of 2.5 (95% CI 1.4–4.5).
The total event rate was low, only 1%, and differed between
low versus high-dose bevacizumab therapy (RR 2.1 [95%
CI 1.1–4.2] vs. 4.8 [95% CI 1.0–22.4]). An elevated risk
was most consistently noted in colorectal cancer patients
(RR 2.1 [95% CI 1.1–4.1]).65
Cerebrovascular events have also been demonstrated in
cancer patients on VSP inhibitor therapy. In a meta-
analysis of 16 RCTs on cerebrovascular events in phase
II and III trials with bevacizumab, the overall incidence
Figure 6.Management proposal for blood
pressure (BP) control of cancer patients
undergoing chemotherapy with hyperten-
sion risk. As outlined in the text, we pro-
pose that patients on VEGF inhibitor
therapy should be treated toward a goal
of <130 mmHg systolic (2017 hyperten-
sion guideline) and <120 mmHg systolic
ideally (SPRINT trial target). Two steps
toward reaching this goal are to be pur-
sued: (1) treatment of contributing and
aggravating factors and (2) antihyperten-
sive therapy by comorbidity.
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5.5), again highest in metastatic colorectal cancer patients
(RR 6.4 [95% CI 1.2–35.6]).66 This analysis was able to
further stratify by stroke type, based on 11 RCTs on
ischemic stroke and seven RCTs on hemorrhagic strokes.
The ischemic stroke incidence was 0.5% (RR 3.2 [95%
CI 1.7–6.1]), highest in metastatic mesothelioma (1.9%).
The hemorrhage stroke incidence was 0.3% (RR 3.1
[95% CI 1.4–7.0]), highest in glioblastoma (1.4%). A
dose-dependent association was noted in this analysis as
well (RR 1.96 [95% CI 0.8–5.1] vs. 3.97 [95% CI 2.2–
7.4]) in low versus high-dose groups.66
With regard to VSP-TKIs, the first meta-analysis was
conducted on 10 RCTs involving sunitinib and sorafenib
with arterial thrombosis, cerebral infarct, cerebral ischemia,
cerebrovascular accident, myocardial infarction, and
myocardial ischemia as ATEs. The incidence was 1.4%
overall and not significantly different between the two che-
motherapeutics (RR 3 [95% CI 1.3–7.4]).50 A subsequent,
more comprehensive meta-analysis in terms of trials (19
RCTs) and endpoints (arterial thrombosis/thromboembo-
lism, cerebral infarct, cerebral ischemia, intestinal
ischemia, ischemic stroke, CV accident, central nervous
system (CNS) ischemia, intracardiac thrombosis, myocar-
dial infarction, myocardia ischemia, defined by the NCI-
CTC criteria) confirmed an overall ATE incidence of
1.5%.67 The highest ATE incidences were noted for cedir-
anib (3.2%) and pazopanib (2.4%), and RRs were
confirmed to be significantly elevated for pazopanib (4.6
[95% CI 1.1–18.7]) and sorafenib (2.3 [95% CI 1.2–4.4])
only. The largest number of events were again noted for
cardiac ischemia/infarction in both TKI and control arm,
and the RR was significantly elevated only for this endpoint(2.6, 95% CI 1.3–5.2). Only patients with renal cell carci-
noma experienced a significantly elevated RR (3, 95% CI
1.4–6.5).67
Mechanisms of Altered Vasoreactivity, Athero-
sclerosis, and Arterial Events with VSP Inhibitors
As outlined above, several studies have evaluated the
impact of VSP inhibition on vascular reactivity, and the
synthesis of these studies is that VEGF inhibitors induce
an imbalance in endothelium-derived vasodilatory and vas-
oconstricting factors. Endothelial dysfunction is a term
often used to describe this condition, and paradoxical vaso-
constriction is one of its hallmarks.68 Furthermore, endo-
thelial dysfunction has a facilitating action on coronary
vasospasm, which, by strict definition, is a functional aber-
ration on vascular smooth muscle cell level.69 Profound
vasospasm has been confirmed in response to ergonovine
and has been implicated in at least one reported case of
sorafenib-induced myocardial infarction.70 Whether this re-
lates to alterations in the activity of the Rho/Rho-associated
protein kinase pathway or other kinases is not known at this
point.69 Potential reasons that this has not been more
commonly reported may include lack of testing and signif-
icant under recognition as well as inter-individual differ-
ences and predispositions, genetic and acquired.
Importantly, the vascular alterations seen with VSP
inhibitor therapy extend into the microvasculature. Coro-
nary microvascular dysfunction, that is, impairment of
the endothelium-dependent and endothelium-independent
vasodilatory response of the coronary microcirculation is
noted after 8 days of sunitinib administration.39,40 In addi-
tion, depletion of microvascular pericytes has been
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may be due to the additional inhibition of PDGF signaling
and adds another layer to endothelial and microvascular
dysfunction.71 Not surprisingly, 70% of patients on suniti-
nib treatment have a reduced coronary flow reserve (on
average 1.8  0.4), especially with longer duration of
therapy.72 The reduced coronary flow reserve can
contribute to presentations of stable and unstable angina
as well as to a reduced myocardial reserve. Acute func-
tional alterations of the coronary microvascular have
also been implicated in Takotsubo’s. The microvascula-
ture might be more susceptible to the effect of VEGF in-
hibitor therapy as under basal conditions human
microvascular but not macrovascular endothelial cells
constitutively generate and release VEGF.73
This being said, arterial endothelial cell culture experi-
ments showed that exposure to a pan-VEGF receptor TKI
increases mitochondrial superoxide generation with un-
coupling of endothelial nitric oxide synthase (eNOS)
and subsequent imbalance in endothelial superoxide and
NO production.74 This profound alteration in endothelial
function predisposes to atherosclerosis, and indeed, cases
of progression of CAD and plaque rupture have been re-
ported for sorafenib and sunitinib, respectively.75,76 In
in vivo experiments, pan-VEGF inhibition markedly
accelerated preexisting atherosclerosis yet without an in-
crease in features of plaque vulnerability (Supplemental
Figure 3).74 These findings are truly intriguing as the ef-
fects of VEGF and VEGF inhibitors on atherosclerosis
have not been without debate. For instance, another exper-
imental study found that bevacizumab reduced plaque
neovascularization and growth similar to the initial studies
with angiogenesis inhibitors.16 The vascular effects of
VEGF and VEGF inhibition may depend on local VEGF
concentrations more than recognized, with low levels
necessary for vascular homeostasis and high concentra-
tions resulting in vasculoproliferative effects. Such dose
dependency may account for the opposing effects
described in different studies and settings. Collectively,
one may conclude though that inhibition of physiological
concentrations of VEGF is associated with accelerated
progression of atherosclerosis, whereas inhibition of su-
pra-physiological levels is of therapeutic value.
Endothelial dysfunction also predisposes to perturbed
hemostasis and vascular thrombosis.68 Hemostasis
is normally regulated by a tight balance between pro-
coagulant and anti-coagulant factors, pro-fibrinolytic
and anti-fibrinolytic factors, and platelet-activating and
platelet-inhibiting factors. The reduction in the produc-
tion of NO and prostacyclins secondary to interference
with the VSP translates into interference with antiplatelet
effects of the endothelium.77 In an elegant study, cancer
patients who developed thromboembolic events with
VSP-TKI therapy were found to have a higher endoge-
nous thrombin potential within 4 weeks of therapy andmuch higher circulating levels of soluble tissue factor
and E-selectin at baseline with further increase- on ther-
apy, which may henceforth serve as potential biomarkers
of CV event risk in these patients.78 Tumors themselves
secrete pro-inflammatory and pro-coagulant factors that
can further promote thromboembolism. Increased blood
viscosity is another mechanism that may contribute to
thromboembolism when VEGF signaling is inhibited.
Finally, VEGF inhibitors such as bevacizumab may act
in a mechanism similar to heparin-induced thrombocyto-
penia. VEGF, like PF4, binds heparin and in immune
complexes with bevacizumab can bind to FCyRIIa
inducing aggregation and pro-coagulant activity.79
Monitoring and Management of Altered Vaso-
reactivity, Atherosclerosis, and Arterial Events
with VSP Inhibitors
Based on the framework provided in their hypertension
assessment and management document, the Cardiovascular
Toxicities Panel of the National Cancer Institute extended
the recommendations to address the aspects outlined
above.80 However, these essentially focus on follow-up
electrocardiograms (ECGs) once on therapy, not only to
monitor for QTc prolongation but also for ischemic ECG
changes. The specific recommendations are for an ECG
at baseline, then at 2–4 weeks, 8–12 weeks, and finally
every 3 months. If ischemic ST-T wave changes were to
be noted, a cardiac evaluation is advised and discretion
should be used in regard to continuation of therapy. If the
patient develops angina (or an abnormal stress test or
angiogram) or suffers an acute myocardial infarction,
VEGF inhibitor therapy is to be discontinued. It was further
recommended not to start VEGF inhibitor therapy in pa-
tients with unstable or poorly controlled angina/myocardial
ischemia at baseline or a recent myocardial or arterial
thrombotic event (and neither in those with uncontrolled
heart failure, uncontrolled arrhythmia, significant QTc pro-
longation, and uncontrolled hypertension). Recommenda-
tions for a more definitive work-up of (clinically silent
and yet significant) ASCVD in patients considered for
VEGF inhibitor therapy were not provided. Neither was
specific guidance suggested on how to manage these pa-
tients through their therapy.
The merit of vasoreactivity testing, ankle-brachial-index,
or carotid-intima media thickness for risk stratification and
the prediction of ATEs with VSP inhibitor therapy are un-
known. Likewise, the predictive value of baseline and
follow-up coronary computed tomography angiography
and noninvasive stress testing is not defined in this popula-
tion, neither for gauging the progression of CAD nor for
predicting acute arterial thrombotic events. Another ques-
tion is if those on VSP inhibitor therapy should be consid-
ered as high risk, as discussed above. All of these questions
are pertinent only as much as the cancer therapy allows
420 R.M. Touyz et al. / Journal of the American Society of Hypertension 12(6) (2018) 409–425these patients to outlive and thus to experience the time dy-
namics of these adverse vascular events, most concerningly
acute myocardial infarction and stroke.
Retrospective analyses have outlined that the incidence
of ATEs on bevacizumab therapy is significantly attenuated
by aspirin in the high-risk group of patients 65 years with
a prior ATE history (12.5% vs. 22.9% in aspirin nonus-
ers).48 This comes at the cost of a difference in grade 3
and 4 bleeding events of 1.1% versus 0.5% in patients
receiving and not receiving bevacizumab, respectively.48
The exact mechanisms of hemorrhage with VSP inhibitor
therapy are unclear but may relate to more profound endo-
thelial damage and endothelial cell apoptosis as well as
platelet dysfunction and are most frequently seen in pa-
tients with gastrointestinal tract or lung cancers.81 In
elegant experimental studies, it was furthermore shown
that various stressors such as oxidative stress and hypoxia
trigger the activation of the VSP by both autocrine and in-
tracrine VEGF sources. The later is critical for endothelial
survival and if impaired by VSP-TKIs, endothelial cell
apoptosis may evolve with the consequences depending
on the environment, that is, hemorrhage and thrombosis
in smaller vessels without and larger vessels with an under-
lying basement membrane (Supplemental Figure 4).82
Taking the bleeding risk into consideration, it is unlikely
that patients are advised to take dual antiplatelet therapy
unless demanded by prior drug-eluting stent placement.
In addition to medications outlined for optimal blood pres-
sure control, the most potent intervention for vascular
health and prevention in these patients may be statin ther-
apy. Statins have been shown to improve NO bioavailability
and eNOS activity. They have been shown to activate phos-
phatidylinositol-3 kinase and AKT signaling, which is sup-
pressed by VEGF. Thus, there have been concerns that
statins may reduce the antiangiogenic and anti-tumor effi-
cacy of VEGF inhibitor. However, statins exert concentra-
tion- and cell type-dependent effects that need to be taken
into consideration. Statins reduce the constitutive VEGF
synthesis of microvascular endothelial cells, whereas they
upregulate VEGF expression in macrovascular endothelial
cells. Furthermore, at low concentrations, they are pro-
angiogenic, whereas at high concentrations, they are
anti-angiogenic.73,83 These dual dynamics have been reca-
pitulated in tumor models, adding to the increasing view
of anticancer effects of statins.84,85 Accordingly, there
should be a low threshold for the use of high-dose statin
therapy in cancer patients who are to or are already under-
going VEGF inhibitor therapy and are at CV risk.
The benefit may be enhanced by the use of amlodipine,
which is often required for blood pressure control in these
patients as outlined above anyway and has been shown to
reduce CV events in patients with mild CAD and even
normal blood pressure along with preventive effects on cor-
onary artery plaque progression.86 Calcium channel
blockers and statins may act synergistically in halting theprogression of atherosclerosis as shown in the Regression
Growth Evaluation Statin Study as well as in experimental
models.87 The combination of atorvastatin and amlodipine
has been shown to improve acute NO release and endothe-
lial function as well as arterial compliance in hypertensive
hyperlipidaemic patients, which seems to be what is needed
in CV risk patients on VSP inhibitor therapy.88
Finally, and even though difficult to accomplish in a can-
cer population, exercise should be advocated to promote
endothelial and vascular health. This is mediated by in-
crease in shear stress, a potent natural inducer of eNOS
via the protein kinase B/AKT pathway. Shear stress-
related effects during exercise are of relatively greater
impact for the macrovasculature (and should thus spare
the tumor microvasculature), even though restores the
endothelial response to VEGF and improves endothelium-
dependent vasodilatation in epicardial coronary vessels
and in resistance vessels.89–91 Exercise has the additional
advantage of improving the CV reserve in general as well
as alerting to any of its potential impairments much sooner
than detected by resting assessments. Accordingly, for pa-
tients with high-CV risk, especially those with atheroscle-
rotic disease and particularly anyone with a history of
clinically evident CAD, CVD, and peripheral arterial dis-
ease should be on a baby aspirin, high-dose statin, possibly
in combination with ACE inhibitor and/or amlodipine ther-
apy and should be asked to exercise routinely (goal for aer-
obic exercise is 3–5 d/wk, 150þ min/wk of moderate
intensity).
If and when to resume cancer therapy in patients who
have experienced a cardiac event is not defined. Clinical tri-
als excluded patients with such an event within 6–12
months of initiation of treatment and often with any clini-
cally significant CVD.43 Angiogenesis is part of the natural
healing response after an acute ischemic event such as
myocardial infarction, and vascular proliferation reaches a
plateau after 2 weeks at which point in time the risk of
hemorrhages declines.92 One may wish to wait until the
response to injury is relatively complete, that is, at least 6
weeks and preferably 90 days. Impaired angiogenesis also
contributes to limb ischemia and reduced wound healing,
for example, after coronary or peripheral artery bypass
grafting. Mechanistically one may further argue that the ef-
fects of VEGF inhibition might be most detrimental in
those patients in whom the system is up-regulated. This
would include patients at risk or in a state of general
ischemia (eg obstructive sleep apnea, reduced cardiac
output, or severe anemia) or with more localized tissue
ischemia (eg severe or unstable angina or transient
ischemic attack).
Summary
Antiangiogenic therapy such as VSP inhibition has
improved outcomes for several cancers but not without
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were to be expected based on the cardinal role of VEGF
in vascular function and health. At present, however, there
are no studies to support any specific strategy, and expert
consensus recommendations are nearly 10 years old. Hy-
pertension is the most commonly seen ‘‘vascular side ef-
fect’’ in patients undergoing VSP inhibitor therapy, but
again, the best management approach to these patients is
not defined. The SPRINT trial, conducted in a patient pop-
ulation at higher CV risk, advocates for more intensive
blood pressure targets (<120 mmHg systolic), and one
may argue that patients undergoing VSP inhibitor therapy
are by default at a higher CV risk based on VEGF-related
impairment in endothelial function and should be more
intensively treated for this reason. Endothelial dysfunction
promotes vasoconstriction, atherosclerosis, platelet activa-
tion, and coagulation, all in favor of ATEs observed in
this patient population. Patients with a prior ATE and
65 years of age are seemingly at highest risk. They in
particular, but preferably anyone with a increased CV risk
as defined, for instance, by the ASCVD risk score or prior
CV history should receive optimal medical therapy with
aspirin, ACE inhibitor, amlodipine, high-dose statin therapy
(Graphical Abstract). Exercise is furthermore promoted to
improve CV health in these patients. The controversial na-
ture of a more intensive management proposal is under-
stood, but these patients now live long enough that CV
complications can have a significant impact and so can pre-
ventive measures.
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